Burjeel Holdings has entered a partnership with US-based Paige for deploying AI approved by the Food and Drug Administration (FDA) in cancer diagnostics across the Middle East and North Africa (MENA).

By integrating Paige’s AI-powered solutions throughout Burjeel’s healthcare network, the move is set to improve access to advanced cancer diagnostics.

The alliance aims to address the shortage of pathologists worldwide by accelerating the availability of faster cancer diagnostics, with a focus on underserved communities and emerging markets.

Paige's suite of AI applications has been developed to back diagnostic decision-making in cancer pathology, and includes Paige Prostate Detect, the first FDA-approved AI algorithm for prostate cancer detection in core-needle biopsies.

Burjeel Holdings is poised to offer these tools, providing cancer care that is both timely and accessible.

Paige’s solutions are developed not only to enhance pathologists’ capabilities but also to streamline workflows.

Burjeel Holdings Group CEO John Sunil said: “By incorporating next-gen AI into our pathology services, we aim to enhance the speed and accuracy of cancer diagnosis, enabling more effective treatment decisions.”

Burjeel Holdings intends to implement Paige’s applications, Paige Breast Lymph Node, Paige PanCancer Detect, and Paige Prostate Detect in conjunction with Paige OmniScreen.

Paige Diagnostics general manager Peter Hamilton said: “This partnership helps deliver on our mission to make next-generation cancer diagnostics accessible worldwide and aligns with our vision to standardise access to cutting-edge diagnostics on a global scale.”

The collaboration marks a significant advancement for Burjeel Holdings, establishing it as a regional centre for AI-driven pathology and setting the stage for the potential expansion of this technology throughout the MENA region and beyond.

Earlier this year, Burjeel Holdings introduced an electronic medical record platform to advance AI adoption and data-driven, evidence-based care.